AngioSoma, Inc. (SOAN)

AngioSoma, Inc. (SOAN) — VMCI valuation read

Composite valuation read on SOAN: VMCI 38/100 against a Healthcare sector median of 50. The 13-point below-median print is the headline number for AngioSoma, Inc., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for SOAN: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on SOAN: SOAN trades at 27.0x earnings, 50% above the Healthcare median of 18.0x; ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp; net debt to EBITDA of 2.9x is the rate-sensitivity line to watch. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

SOAN rose 2.3% over the trailing 7 days, with a -10.7% read on a 30-day basis.